-
公开(公告)号：EP4410298A2
公开(公告)日：2024-08-07
申请号：EP24182877.1
申请日：2020-04-17
申请人： Biogaia AB
发明人： ROOS, Stefan , KUNZE, Wolfgang , BIENENSTOCK, John
IPC分类号： A61K35/747
CPC分类号： A61K35/745 , A61K35/747 , A61P1/00 , C12N1/20 , C12R2001/0120210501 , C12N1/205
摘要： A method to provide therapeutic microvesicles from probiotic bacteria comprises exposing the bacteria to an inducing treatment during culturing to induce production and release of therapeutic microvesicles by the bacteria. The therapeutic microvesicles may be used in treatment of, for instance, colic, an infant or childhood gastrointestinal disorder or disease, a gastrointestinal pain disorder, a bone loss disease and/or a periodontal disease.
-
公开(公告)号：EP4253571A3
公开(公告)日：2023-12-13
申请号：EP23186579.1
申请日：2020-11-06
申请人： Biogaia AB
发明人： GRASSET, Estelle , KHAN, Muhammad , MÖLLSTAM, Bo , ROOS, Stefan
IPC分类号： A61P25/00 , A23L33/135 , A61K35/747 , C12N1/20 , C12R1/225 , C12R1/25
摘要： The invention relates to selection of bacterial strain for use in treating a disease related to serotonin deficiency by culturing bacteria of a lactic acid producing bacterial strain, under aerobic conditions, in a culture medium comprising tryptophan. Any serotonin produced by the bacteria of the lactic acid producing bacterial strain in the culture medium is detected and the lactic acid producing bacterial strain is selected as effective in treating serotonin deficiency and/or a disease related to serotonin deficiency in a subject if serotonin is detected in the culture medium.
-
-
公开(公告)号：EP4152963A1
公开(公告)日：2023-03-29
申请号：EP22712094.6
申请日：2022-03-11
申请人： Biogaia AB
发明人： ROOS, Stefan , HORCAJADA, Marie Noëlle , BONNET, Nicolas , SABATIER, Magalie , BOURQUI, Bertrand , PRIOULT, Guénolée Eliane Marie , DE BRUYN, Florac
IPC分类号： A23L33/135 , A23L33/125
-
公开(公告)号：EP4152962A1
公开(公告)日：2023-03-29
申请号：EP22710204.3
申请日：2022-03-11
申请人： Biogaia AB
发明人： ROOS, Stefan , HORCAJADA, Marie Noëlle , BONNET, Nicolas , SABATIER, Magalie , BOURQUI, Bertrand , PRIOULT, Guénolée Eliane Marie , DE BRUYN, Florac
IPC分类号： A23L33/135 , C12N1/20 , A23L33/125
-
公开(公告)号：EP3369808A1
公开(公告)日：2018-09-05
申请号：EP18167810.3
申请日：2013-09-03
申请人： Biogaia AB
IPC分类号： C12N1/20 , A61K35/747 , C12R1/225
CPC分类号： A61K35/74 , A23L33/135 , A23V2002/00 , A61K35/747 , A61K49/0004 , A61K2035/11 , C12N1/20 , C12R1/225 , G06T7/0012 , G06T7/13 , G06T2207/30092
摘要： A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises:
a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyse the effect of said agent on gastrointestinal motility; and
b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyse the effect of said agent on mesenteric afferent nerve firing.
Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided.-
7.发明授权A METHOD FOR SELECTION OF AGENTS INFLUENCING INTESTINAL MOTILITY DISORDERS AND PAIN 有权选择影响肠道运动障碍和疼痛的药物的方法
公开(公告)号：EP2893045B1
公开(公告)日：2018-05-16
申请号：EP13756897.8
申请日：2013-09-03
申请人： Biogaia AB
CPC分类号： A61K35/74 , A23L33/135 , A23V2002/00 , A61K35/747 , A61K49/0004 , A61K2035/11 , C12N1/20 , C12R1/225 , G06T7/0012 , G06T7/13 , G06T2207/30092
摘要： A method is provided for evaluating agents for the treatment of different intestinal motility disorders, using distinct methodological parts related to musculature and nerves of the GI tract which communicate with the brain. In particular, the present invention provides a method for the selection of an agent effective for the treatment of an intestinal motility disorder, wherein said method comprises: a) a step of spatiotemporal (ST) mapping carried out on a gastrointestinal segment to analyse the effect of said agent on gastrointestinal motility; and b) a step of ex vivo nerve bundle recording carried out on a gastrointestinal segment to analyse the effect of said agent on mesenteric afferent nerve firing. Bacterial strains selected by the methods of the invention and the use of said bacterial strains in the treatment of intestinal motility disorders are also provided.
-
8.发明授权CONTROLLED ACTIVATION OF THE REUTERIN-PRODUCTION MACHINERY OF LACTOBACILLUS REUTERI 有权罗伊氏乳杆菌的罗伊氏机械生产受控启动
公开(公告)号：EP2303295B1
公开(公告)日：2015-09-30
申请号：EP09762760.8
申请日：2009-06-10
申请人： Biogaia AB
发明人： ROOS, Stefan
摘要： Methods for the controlled activation of the reuterin-production machinery of Lactobacillus reuteri by adding glycerol and other substances during the manufacture of cell-cultures and keeping the produced reuterin in the bacterial cell during preservation and storage. In particular this invention relates to the manufacture of large amounts of L. reuteri that are loaded with reuterin, and the use of such loaded bacteria for applications such as prevention and treatment of diseases, for food applications and the like.
-
9.发明公开LACTOBACILLUS REUTERI DSM 17938 FOR THE DEVELOPMENT OF COGNITIVE FUNCTION 审中-公开罗伊氏乳杆菌DSM 17938认知功能的发育
公开(公告)号：EP2797434A1
公开(公告)日：2014-11-05
申请号：EP12791792.0
申请日：2012-11-30
申请人： Biogaia AB
CPC分类号： A61K35/74 , A23L33/135 , A23L33/40 , A23V2002/00 , A23Y2220/71 , A61K35/747 , A61K2035/115 , A23V2200/322
摘要： The invention relates to Lactobacillus reuteri DSM 17938 for promoting the establishment of healthy and normal cognitive function in young mammals. In particular, the invention relates to the use of Lactobacillus reuteri DSM 17938 for promoting development of the brain structures responsible for cognitive functions (e.g. cortex and hippocampus) and its associated neural pathways and/or to reverse retardation and/or to prevent retardation of the establishment of cognitive functions. Humans or animals and, in particular, a foetus, pre- term or term born infant, toddler or child or a young adult may benefit from the invention.
-
10.发明公开PRODUCTION AND USE OF BACTERIAL HISTAMINE 审中-公开HERSTELLUNG UND VERWENDUNG VON BAKTERIELLEM HISTAMIN
公开(公告)号：EP2734845A1
公开(公告)日：2014-05-28
申请号：EP12738122.6
申请日：2012-07-20
申请人： Biogaia AB
IPC分类号： G01N33/569 , A23L1/30 , A61K35/74
CPC分类号： A61K35/747 , A23L33/135 , A23L33/175 , A23V2002/00 , A23Y2220/71 , A61K31/4172 , A61K31/7004 , A61K35/74 , A61K35/741 , A61K45/06 , A61K2035/115 , C12Q1/04 , G01N33/56911 , G01N2333/335 , A23V2200/324
摘要： A method is provided of selecting specific probiotic lactic acid bacteria producing histamine and the use of such strains for beneficial effects for mammals. The method includes selecting a lactic acid bacterial strain for use in the local production of histamine in a mammal, and further comprises screening bacteria for the presence of an active histidine operon and selecting a strain which has an active histidine operon and is capable of producing histamine. Preferably said strain is selected for its ability to produce histamine at a level of greater than 250 pg/ml. The present invention further provides products comprising the strains obtainable by the selection methods of the invention for use in the local production of histamine in a mammal, in particular for use in the treatment or prophylaxis of inflammatory conditions.
摘要翻译： 提供一种选择产生组胺的特定益生菌乳酸菌的方法以及这些菌株对哺乳动物的有益作用的使用。 该方法包括选择用于哺乳动物局部生成组胺的乳酸菌株，并且还包括筛选细菌以存在活性组氨酸操纵子并选择具有活性组氨酸操纵子并且能够产生组胺的菌株 。 优选地，选择所述菌株以其大于250pg / ml的水平产生组胺的能力。 本发明还提供了包含通过本发明的选择方法可获得的用于在哺乳动物中局部产生组胺的菌株的产品，特别是用于治疗或预防炎性病症的产品。
-
-
-
-
-
-
-
-
-
搜索结果
103 条记录 (耗时 0.022 秒)
